$PLSE
PULSE BIOSCIENCES, INC.

2024 Q4 Form 10-Q Financial Statement

#000143774924032614 Filed on October 30, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.952M
YoY Change 57.46%
% of Gross Profit
Research & Development $7.703M
YoY Change 3.09%
% of Gross Profit
Depreciation & Amortization $100.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $7.703M
YoY Change 3.09%
Operating Profit -$13.66M
YoY Change 21.36%
Interest Expense $975.0K
YoY Change 42.13%
% of Operating Profit
Other Income/Expense, Net $975.0K
YoY Change 42.13%
Pretax Income -$12.68M
YoY Change 20.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$12.68M
YoY Change 20.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$0.21
COMMON SHARES
Basic Shares Outstanding 61.52M 61.29M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.03M
YoY Change 56.84%
Cash & Equivalents $79.03M
Short-Term Investments
Other Short-Term Assets $1.381M
YoY Change 11.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $80.41M
YoY Change 55.77%
LONG-TERM ASSETS
Property, Plant & Equipment $1.221M
YoY Change -25.91%
Goodwill $2.791M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $646.0K
YoY Change 76.99%
Total Long-Term Assets $12.63M
YoY Change -11.8%
TOTAL ASSETS
Total Short-Term Assets $80.41M
Total Long-Term Assets $12.63M
Total Assets $93.05M
YoY Change 41.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.727M
YoY Change 22.31%
Accrued Expenses $3.821M
YoY Change 27.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.741M
YoY Change 24.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $7.174M
YoY Change -14.29%
Total Long-Term Liabilities $7.174M
YoY Change -14.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.741M
Total Long-Term Liabilities $7.174M
Total Liabilities $13.92M
YoY Change 0.83%
SHAREHOLDERS EQUITY
Retained Earnings -$371.1M
YoY Change 14.2%
Common Stock $450.2M
YoY Change 19.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $79.13M
YoY Change
Total Liabilities & Shareholders Equity $93.05M
YoY Change 41.1%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$12.68M
YoY Change 20.01%
Depreciation, Depletion And Amortization $100.0K
YoY Change 0.0%
Cash From Operating Activities -$9.024M
YoY Change -13.98%
INVESTING ACTIVITIES
Capital Expenditures $38.00K
YoY Change 90.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$38.00K
YoY Change 90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 61.90M
YoY Change 2792.48%
NET CHANGE
Cash From Operating Activities -9.024M
Cash From Investing Activities -38.00K
Cash From Financing Activities 61.90M
Net Change In Cash 52.84M
YoY Change -731.27%
FREE CASH FLOW
Cash From Operating Activities -$9.024M
Capital Expenditures $38.00K
Free Cash Flow -$9.062M
YoY Change -13.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Pulse Biosciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001625101
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61516000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61516000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55144000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55144000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
9000 usd
CY2023 plse Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 usd
plse Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 usd
CY2023Q3 us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
400000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2023Q1 us-gaap Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration
RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CostsAndExpenses
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34899
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5696597
dei Entity Address Address Line1
EntityAddressAddressLine1
601 Brickell Key Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Miami
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33131
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
906-4600
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
PLSE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61516677
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79033000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44365000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1381000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
963000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
80414000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45328000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1221000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1528000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1386000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1886000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
2791000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
2791000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6588000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7256000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
646000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000 usd
CY2024Q3 us-gaap Assets
Assets
93046000 usd
CY2021Q4 us-gaap Assets
Assets
59154000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1727000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1836000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3821000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3814000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1193000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1058000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6741000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6708000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7174000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8086000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
13915000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
14794000 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
62000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
55000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
450184000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
381220000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-371115000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-336915000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
79131000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44360000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93046000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59154000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7703000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7472000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21674000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19998000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5952000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3780000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14322000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11043000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
13655000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
11252000 usd
us-gaap Costs And Expenses
CostsAndExpenses
35996000 usd
us-gaap Costs And Expenses
CostsAndExpenses
31041000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13655000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11252000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-35996000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-31041000 usd
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
975000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
686000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1796000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
764000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
975000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
686000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1796000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
764000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12680000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10566000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34200000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30277000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12680000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10566000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30277000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12680000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10566000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34200000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30277000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61066000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56866000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57169000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47288000
us-gaap Net Income Loss
NetIncomeLoss
-34200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30277000 usd
us-gaap Depreciation
Depreciation
391000 usd
us-gaap Depreciation
Depreciation
404000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
499000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6793000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3837000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
394000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
343000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-7000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-114000 usd
plse Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-668000 usd
plse Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-596000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-174000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
409000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-777000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-656000 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
0 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
-668000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27199000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26259000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
72000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-78000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
478000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
395000 usd
plse Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
59649000 usd
plse Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1536000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
14828000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
498000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
367000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
-0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
6000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
222000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61939000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15584000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34668000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10753000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44365000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61139000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79033000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50386000 usd
plse Equipment Purchases Included In Accounts Payable And Accrued Expenses
EquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
13000 usd
plse Equipment Purchases Included In Accounts Payable And Accrued Expenses
EquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
13000 usd
plse Right Offering Deemed Dividend
RightOfferingDeemedDividend
47700000 usd
plse Right Offering Deemed Dividend
RightOfferingDeemedDividend
0 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
65249000 usd
plse Other Receivable From Exercise Of Warrants
OtherReceivableFromExerciseOfWarrants
30000 usd
plse Other Receivable From Exercise Of Warrants
OtherReceivableFromExerciseOfWarrants
0 usd
plse Issuance Costs Incurred In Noncash Or Part Noncash Transaction
IssuanceCostsIncurredInNoncashOrPartNoncashTransaction
72000 usd
plse Issuance Costs Incurred In Noncash Or Part Noncash Transaction
IssuanceCostsIncurredInNoncashOrPartNoncashTransaction
0 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
26969000 usd
CY2024Q3 plse Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1566000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
476000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
182000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2982000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12680000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
79131000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
44360000 usd
plse Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1566000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
498000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
478000 usd
plse Equity Classified Subscription Value
EquityClassifiedSubscriptionValue
47700000 usd
plse Right Offering Deemed Dividend
RightOfferingDeemedDividend
47700000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6793000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34200000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
79131000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
60500000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
309000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
103000 usd
CY2023Q3 plse Adjustments To Additional Paid In Capital Warrants Exercise Issuance Cost Adjustment
AdjustmentsToAdditionalPaidInCapitalWarrantsExerciseIssuanceCostAdjustment
1000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1798000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10566000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
52145000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2248000 usd
plse Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
14828000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
395000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
367000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3837000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30277000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
52145000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but are <em style="font: inherit;">not</em> limited to, the valuation and recognition of stock-based compensation, the valuation of equity-classified subscription rights, inventory valuation, warranty obligations, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2024Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
0 usd
CY2023Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
0 usd
CY2023Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
0 usd
CY2022Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
50000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
0 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
0 usd
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
0 usd
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
0 usd
CY2024Q3 plse Adjustment For Inventory At Cost
AdjustmentForInventoryAtCost
0 usd
CY2023Q3 plse Adjustment For Inventory At Cost
AdjustmentForInventoryAtCost
0 usd
plse Adjustment For Inventory At Cost
AdjustmentForInventoryAtCost
0 usd
plse Adjustment For Inventory At Cost
AdjustmentForInventoryAtCost
-50000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
0 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
0 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
0 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18185012
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7902948
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
76386000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
41184000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5089000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5004000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3868000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3476000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1221000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1528000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
400000 usd
CY2024Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6599000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6099000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1386000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1886000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
165000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
665000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
556000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1386000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3111000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3199000 usd
CY2024Q3 plse Accrued Clinical Trial Fees And Costs
AccruedClinicalTrialFeesAndCosts
80000 usd
CY2023Q4 plse Accrued Clinical Trial Fees And Costs
AccruedClinicalTrialFeesAndCosts
84000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
424000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
343000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
206000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
188000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3821000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3814000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2982000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1798000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6793000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3837000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2982000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1798000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6793000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3837000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6588000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7256000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1193000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1058000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7174000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8086000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8367000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
9144000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1425000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1376000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
485000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1977000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2046000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2117000 usd
CY2024Q3 plse Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
4074000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10699000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2332000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8367000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y29D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10 pure
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000 usd

Files In Submission

Name View Source Status
0001437749-24-032614-index-headers.html Edgar Link pending
0001437749-24-032614-index.html Edgar Link pending
0001437749-24-032614.txt Edgar Link pending
0001437749-24-032614-xbrl.zip Edgar Link pending
ex_722415.htm Edgar Link pending
ex_722416.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plse-20240930.xsd Edgar Link pending
plse20240930c_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
plse-20240930_cal.xml Edgar Link unprocessable
plse-20240930_def.xml Edgar Link unprocessable
plse-20240930_lab.xml Edgar Link unprocessable
plse-20240930_pre.xml Edgar Link unprocessable
plse20240930c_10q_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable